• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Cain Christopher W.

    3/12/25 4:17:38 PM ET
    $VRDN
    Medical Specialities
    Health Care
    Get the next $VRDN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    CAIN CHRISTOPHER W.

    (Last) (First) (Middle)
    C/O VIRIDIAN THERAPEUTICS, INC.
    221 CRESCENT STREET, SUITE 103A

    (Street)
    WALTHAM MA 02453

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/10/2025
    3. Issuer Name and Ticker or Trading Symbol
    Viridian Therapeutics, Inc.\DE [ VRDN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Jennifer Tousignant, Attorney-in-fact 03/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VRDN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRDN

    DatePrice TargetRatingAnalyst
    12/19/2024$37.00 → $27.00Overweight → Equal Weight
    Wells Fargo
    11/25/2024Buy
    TD Cowen
    9/11/2024$30.00 → $38.00Buy
    Needham
    6/11/2024$29.00Outperform
    Wolfe Research
    6/6/2024$23.00Buy
    Goldman
    5/9/2024Buy → Neutral
    Ladenburg Thalmann
    5/9/2024$25.00 → $20.00Buy → Neutral
    B. Riley Securities
    6/14/2023$51.00Outperform
    Credit Suisse
    More analyst ratings

    $VRDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

      SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

      11/14/24 5:53:44 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

      SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

      11/14/24 5:52:18 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

      SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

      11/14/24 4:50:30 PM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

      - Breakthrough Therapy Designation request based on veligrotug's (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response - - Veligrotug met all of its primary and secondary endpoints in the pivotal THRIVE and THRIVE-2 clinical trials in active and chronic TED - - First and only drug candidate in chronic TED to demonstrate statistically significant and clinically meaningful improvement and resolution of diplopia in a global phase 3 clinical trial - - Breakthrough Therapy Designation supports eligibility for Priority Review - - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 wit

      5/7/25 4:15:00 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

      - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye disease (TED), are on track for topline data in the first half of 2026 - - VRDN-006 clinical data in healthy volunteers on track for third quarter 2025 - - VRDN-008, a bispecific neonatal Fc receptor (FcRn) inhibitor with an extended half-life, on track for an Investigational New Drug (IND) submission for year-end 2025 - - Appointed Jeff Ajer, long-time Chief Commercial Officer of BioMarin, to Viridian's Board

      5/6/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 204,150 shares of the company's common stock to 13 new employees (the "Inducement Grants") on May 1, 2025 (the "Grant Date"). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the "Plan") but remain subject to the terms and conditions of

      5/2/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Financials

    Live finance-specific insights

    See more
    • Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

      - Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global phase 3 study in patients with chronic TED to demonstrate a statistically significant and clinically meaningful 56% diplopia responder rate (placebo-adjusted rate of 31%, p = 0.0006) and 32% rate of diplopia complete resolution (placebo-adjusted rate of 18%, p = 0.0152) - - Veligrotug was generally well-tolerated with 94% of patients completing their treatment course and a 9.6% placebo-adjusted rate of hearing impairment - - BLA submission for veligrotug

      12/16/24 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

      - THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presenta

      12/13/24 6:00:00 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

      - Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of 70% and a placebo-adjusted PRR of 64% (p < 0.0001) - - All secondary endpoints were highly statistically significant (p < 0.0001), with clinically meaningful patient outcomes, including complete resolution of diplopia in 54% of patients (placebo-adjusted rate of 43%) and reduction of Clinical Activity Score (CAS) to 0 or 1 in 64% of patients (placebo-adjusted reduction of 46%) treated with veligrotug - - Veligrotug was generally well-tolerated with no treatment-r

      9/10/24 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Leadership Updates

    Live Leadership Updates

    See more
    • Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

      - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye disease (TED), are on track for topline data in the first half of 2026 - - VRDN-006 clinical data in healthy volunteers on track for third quarter 2025 - - VRDN-008, a bispecific neonatal Fc receptor (FcRn) inhibitor with an extended half-life, on track for an Investigational New Drug (IND) submission for year-end 2025 - - Appointed Jeff Ajer, long-time Chief Commercial Officer of BioMarin, to Viridian's Board

      5/6/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

      - Mr. Ajer was most recently Chief Commercial Officer at BioMarin - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement, and sales operations. He most recently served as the Executive Vice President and Chief Commercial Officer (CCO) at BioMarin Pharmaceutical, where he joined in 20

      4/7/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

      - Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing Q4W or Q8W subcutaneous (SC) VRDN-003 in active and chronic TED, progressing as planned and on track for topline data for both trials in the first half of 2026 - - Proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter o

      2/27/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Viridian Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Viridian Therapeutics from Overweight to Equal Weight and set a new price target of $27.00 from $37.00 previously

      12/19/24 8:33:15 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • TD Cowen initiated coverage on Viridian Therapeutics

      TD Cowen initiated coverage of Viridian Therapeutics with a rating of Buy

      11/25/24 7:56:18 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Needham reiterated coverage on Viridian Therapeutics with a new price target

      Needham reiterated coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $38.00 from $30.00 previously

      9/11/24 8:00:48 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Beetham Thomas W. bought $117,050 worth of shares (5,000 units at $23.41), increasing direct ownership by 500% to 6,000 units (SEC Form 4)

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      9/30/24 7:12:50 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • President and CEO Mahoney Stephen F. bought $499,262 worth of shares (21,400 units at $23.33) (SEC Form 4)

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      9/30/24 7:10:58 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Director Fairmount Funds Management Llc bought $30,000,000 worth of shares (1,600,000 units at $18.75) (SEC Form 4)

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      9/17/24 9:00:13 PM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Viridian Therapeutics Inc.

      10-Q - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

      5/6/25 7:55:45 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

      5/6/25 7:28:38 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Viridian Therapeutics Inc.

      DEFA14A - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

      4/25/25 7:57:02 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ajer Jeffrey Robert

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      4/9/25 4:26:02 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Ajer Jeffrey Robert

      3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      4/9/25 4:19:55 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Tripuraneni Radhika

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      3/12/25 4:36:26 PM ET
      $VRDN
      Medical Specialities
      Health Care